Test Price
2,800 AED✅ Home Collection Available
MEGF10 Gene Myopathy, Early-Onset Genetic Test in UAE
Executive Summary & Core Metrics
Clinical Utility: Definitive molecular diagnosis of MEGF10-related early-onset myopathy, areflexia, respiratory distress, and dysphagia (EMARDD) via full gene sequencing.
Accuracy: 99.9% diagnostic sensitivity using Next-Generation Sequencing (NGS) at our ISO 15189-accredited processing facility.
Price: 2,800 AED – includes pre-test genetic counselling, analysis, and a complimentary telephonic post-test clinical guidance session with a DHA-licensed genetic counsellor.
Turnaround Time: 3–4 weeks from sample receipt.
Sample Type: Peripheral whole blood, extracted DNA, or FTA card (dried blood spot).
Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The MEGF10 Gene Myopathy, Early-Onset Genetic Test is a comprehensive molecular assay that sequences the entire coding region and exon-intron boundaries of the MEGF10 gene using Next-Generation Sequencing (NGS) with copy number variant (CNV) detection. This test provides a definitive diagnosis for EMARDD, a congenital myopathy characterised by hypotonia, areflexia, respiratory distress, and feeding difficulties. Accurate genetic confirmation guides prognosis, management, and family planning.
| Feature | Our NGS MEGF10 Test | Standard Single-Gene / Panel |
|---|---|---|
| Methodology | Full MEGF10 gene sequencing with CNV analysis via NGS | Sanger sequencing (targeted exons only) or neuromuscular panel with limited coverage |
| Diagnostic Yield | >99% for point mutations, indels, and large rearrangements | May miss deep intronic variants or exonic deletions; lower sensitivity |
| Clinical Efficiency | Definitive result in 3–4 weeks, avoiding invasive muscle biopsy | Often requires reflex testing; diagnostic odyssey prolonged by months |
Physician Insight & Safety Protocols
Insight from Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403): “Interpretation of MEGF10 results requires careful genotype-phenotype correlation. A pathogenic variant confirms EMARDD and enables targeted surveillance and family counselling. However, a negative result does not rule out all neuromuscular disorders and should prompt consideration of broader genetic testing. Always integrate this result with the full clinical picture under the guidance of a specialist neurologist.”
Advisory & Medication Precautions
Important Medication Warning
Do not discontinue prescribed respiratory support, feeding modifications, or any anti-epileptic or cardiac medications without consulting your primary neurologist. This genetic test does not replace ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion from Home Collection: Patients under 12 years of age require hospital-based collection per Federal Law No. 2 of 2019 on health information technology. Also, individuals on non-invasive ventilation (NIV) or tracheostomy without a dedicated escort nurse are not eligible for home phlebotomy.
- Specimen Rejection Criteria: Hemolyzed blood samples, insufficient DNA quantity on FTA cards, or samples not maintained in our ISO-certified cold chain will be rejected.
- Emergency Red Flags: Seek immediate emergency care for acute worsening of respiratory distress, oxygen saturation below 90% on room air, or sudden inability to swallow (dysphagia) with aspiration risk. This test is not an emergency diagnostic tool.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the MEGF10 gene test for early-onset myopathy?
This DNA test is the gold standard for definitively diagnosing MEGF10-related EMARDD by identifying disease-causing mutations, ending the diagnostic odyssey, and enabling targeted management, respiratory and feeding support, and genetic counselling for the family.
2. How does NGS methodology improve diagnosis over older tests?
Next-Generation Sequencing simultaneously analyses all exons and exon-intron boundaries of the MEGF10 gene with high read depth. It detects not only point mutations but also copy number variations (CNVs) that Sanger sequencing would miss, providing the most comprehensive molecular diagnosis available.
3. What are the data privacy protections for my genetic information in the UAE?
Your genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All results are anonymised and stored securely; they cannot be used for insurance or employment discrimination.
4. Is a doctor’s referral required for this test?
Yes, a referral from a neurologist, paediatrician, or geneticist is strongly recommended. A mandatory pre-test genetic counselling session is required to draw a family pedigree and discuss implications.
UAE Regulatory & Data Privacy Adherence
Data Privacy: All genetic test results are handled in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Medical Liability & Consent: Pre-test counselling and informed consent are obtained in line with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditation: DNA Labs UAE operates under DHA Facility License No. 1143 and is ISO 15189 accredited (Cert: INT/EGQ/2509DA/3139) for genetic testing. Our services meet the highest standards of quality and safety.
Clinical & Logistical Metadata
| Test Name | MEGF10 Gene Myopathy, Early-Onset Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood, extracted DNA, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV detection |
| ICD-10-CM Code | G71.0 (Congenital muscular dystrophy – applicable to EMARDD phenotype) |
| LOINC Code | 82939-0 (MEGF10 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians